Clinical Trial Update: Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacokinetics of topical AH-001 for androgenetic alopecia; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• AH-001

Snippet

Sponsor: AnHorn Medicines Co. Ltd. | Conditions: Androgenetic Alopecia | Phase 1 | Status: COMPLETED